Avalyn Pharma (NASDAQ:AVLN) Upgraded by Guggenheim to Strong-Buy Rating

Avalyn Pharma (NASDAQ:AVLN) was upgraded by equities researchers at Guggenheim to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other research firms also recently commented on AVLN. Morgan Stanley initiated coverage on shares of Avalyn Pharma in a report on Tuesday. They issued an “overweight” rating and a $53.00 price objective for the company. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group initiated coverage on Avalyn Pharma in a report on Monday. They set a “buy” rating and a $52.00 price objective on the stock. Finally, Evercore began coverage on Avalyn Pharma in a report on Tuesday. They set an “outperform” rating and a $51.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, Avalyn Pharma has an average rating of “Strong Buy” and a consensus price target of $59.00.

Avalyn Pharma Price Performance

Shares of NASDAQ:AVLN opened at $26.70 on Monday. Avalyn Pharma has a twelve month low of $25.05 and a twelve month high of $32.22.

Insiders Place Their Bets

In other Avalyn Pharma news, Director Jill Carroll acquired 277,778 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the purchase, the director owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This represents a 14.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of Avalyn Pharma stock in a transaction that occurred on Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the transaction, the insider owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 34.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.